




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 31/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/09618</b> <b>(43) International Publication Date:</b> 12 March 1998 (12.03.98)																		
<b>(21) International Application Number:</b> PCT/US97/15572 <b>(22) International Filing Date:</b> 3 September 1997 (03.09.97) <b>(30) Priority Data:</b> 08/709,650 9 September 1996 (09.09.96) US <b>(71) Applicant:</b> SANGSTAT MEDICAL CORPORATION [US/US]; 1505-B Adams Drive, Menlo Park, CA 94025 (US). <b>(72) Inventors:</b> BUELOW, Roland; 2747 Ross Road, Palo Alto, CA 94303 (US). WOO, Jacky; 620 Iris Avenue #422, Sunnyvale, CA 94086 (US). IYER, Suhasini; 1 Elmwood Drive, San Ramon, CA 94583 (US). <b>(74) Agents:</b> CHICKERING, Robert, B. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>																		
<b>(54) Title:</b> GRAFT SURVIVAL PROLONGATION, WITH PORPHYRINS   <table border="1"><caption>Data points estimated from the graph</caption><thead><tr><th>Concentrations (ug/ml)</th><th>ZnPP (% Lysis)</th><th>CoPP (% Lysis)</th></tr></thead><tbody><tr><td>10<sup>-2</sup></td><td>22</td><td>22</td></tr><tr><td>10<sup>-1</sup></td><td>24</td><td>23</td></tr><tr><td>10<sup>0</sup></td><td>20</td><td>16</td></tr><tr><td>10<sup>1</sup></td><td>13</td><td>8</td></tr><tr><td>10<sup>2</sup></td><td>5</td><td>-18</td></tr></tbody></table> <b>(57) Abstract</b> Metalloporphyrins are administered in conjunction with transplantation to enhance the survival of the organ.			Concentrations (ug/ml)	ZnPP (% Lysis)	CoPP (% Lysis)	10 <sup>-2</sup>	22	22	10 <sup>-1</sup>	24	23	10 <sup>0</sup>	20	16	10 <sup>1</sup>	13	8	10 <sup>2</sup>	5	-18
Concentrations (ug/ml)	ZnPP (% Lysis)	CoPP (% Lysis)																		
10 <sup>-2</sup>	22	22																		
10 <sup>-1</sup>	24	23																		
10 <sup>0</sup>	20	16																		
10 <sup>1</sup>	13	8																		
10 <sup>2</sup>	5	-18																		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NF	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## GRAFT SURVIVAL PROLONGATION WITH PORPHYRINS

### BACKGROUND

The inflammatory process is an extraordinarily complex process, varying with the cause of inflammation, the site of the inflammation, and the nature of the insult. Numerous different types of leukocytes are attracted to the site where the inflammatory process is initiated. The different leukocytes initiate different biological processes to respond to the insult. While in many situations, the inflammatory response is healthy in destroying a pathogen, in other situations, such as autoimmune diseases and transplantation, the inflammatory response is undesirable. In the latter case, this leads to rejection and loss of the implanted organ, which in most cases will be fatal.

A number of different avenues have been investigated to encourage the retention of allografts. For the most part, these avenues have involved general immunosuppression, using drugs such as cyclosporin and FK 506. Extensive efforts have been directed to inducing anergy toward the foreign tissue. Also, the role of various factors has been investigated, where by modulating the level of the factors, the immune response may be diminished. For the most part, the primary approach has been the use of drugs which suppress the entire immune system, therefore leaving the patient vulnerable to adventitious infection.

Because of the restricted availability of donor organs, consideration has been given to using xenografts for temporary maintenance, while an acceptable allogenic organ is identified. The xenografts not only differ as to the MHC, but will also have numerous other epitopes differing from the host. Therefore, additional rejection mechanisms are brought to bear against the xenograft.

There is a pressing need to find alternative modalities which provide protection against transplant rejection. These modalities may find use in conjunction with other drugs, where lower levels of other drugs having significant side effects may be used effectively, so as to reduce the detrimental side effects.

- 5 Thus, there is substantial interest in developing new approaches to reducing the rejection phenomenon, where the drug may act by itself or in conjunction with other drugs.

#### BRIEF DESCRIPTION OF THE RELEVANT LITERATURE

- 10 Heme oxygenase has been the subject of numerous studies as evidenced by the review article, Abraham et al., *Int. J. Biochem.* (1988) 20(6):543-558. Recently, modulation of heme oxygenase activity has been described in Raju and Maines, *Biochimica et Biophysica Acta* (1994) 1217:273-280; Neil et al. *J. of Ocular Pharmacology and Therapeutics* (1995) 11(3):455-468; Haga et al., *ibid.* 15 (1996) 1316:29-34; Willis et al., *Nature Medicine* (1996) 2(1):87-90; and Agarwal et al., *Transplantation* (1996) 61(1):93-98.

#### SUMMARY OF THE INVENTION

- Transplant survival in mammalian hosts is enhanced by providing a  
20 therapeutic dose of a metallic protoporphyrin in conjunction with the transplantation. Specifically, inhibitory metallic protoporphyrins are employed in an amount sufficient to inhibit heme oxygenase at a time proximal to the time of transplant, whereby the survival of the transplant is extended.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- 25 Figure 1 is a graph of the inhibition of target cell lysis by metalloprotoporphyrins. T-cell mediated cell lysis was evaluated in the presence of varying amounts of Zn- and Co-protoporphyrin in a four hour chromium release assay;
- 30 Figure 2 is a graph showing the prolongation of heart allograft survival following metalloprotoporphyrin therapy. CBA recipients of C57B1/6 heart allografts were either untreated or treated as follows: ZnPP group (n=4); Zn-protoporphyrin was administered at 10 mg/kg/day on day -1 before transplantation

and on days 1-9 post transplantation. CoPP group (n=4); Co-protoporphyrin was administered at 20 mg/kg/day on days 0-5 post-transplantation; ZnPP pretreatment group (n=3); heart donors were treated one day before transplantation with 50 mg/kg Zn-protoporphyrin.

5

### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods are provided for prolonging the acceptance of transplants in a mammalian host. The method employs the administration of a metalloprotoporphyrin prior to concomitant with, subsequent to or a combination thereof with the transplant. A particular regimen is employed for administration, where a single bolus or plurality of doses may be administered to the recipient and/or donor, before, concomitant with, or subsequent to the implanting of the organ in the recipient. The particular protocol will depend upon the nature of the organ, the particular metalloprotoporphyrin which is employed, and the use of other immunosuppressants.

Administration will usually begin within 7 days prior to the transplant, preferably within about 3 days, and desirably will include the day prior to the transplant and particularly, the same day as and/or the day after the transplantation. Administration may be on consecutive days or non-consecutive days, generally any gap being fewer than 10 days. Administration concomitant with the transplant or on the same day may be useful, but preferably in most instances administration will begin on the first day after the transplant and may be continued until the transplant is stabilized, generally not exceeding one month, more usually not exceeding two weeks. The metalloprotoporphyrin may also be administered to the donor, usually within three days of the removal of the organ, more usually not later than the day prior to removal of the organ, desirably within about 12 hours of the removal of the organ.

A number of different metalloprotoporphyrins are known, which have been used for the inhibition of heme oxygenase. Depending upon the nature of the particular metal which is chelated by the protoporphyrin, and the protocol employed, either induction or inhibition of the heme oxygenase is observed. Contradictory reports exist in the literature as to the effect of the particular metal. Abraham et al., *Int. J. Biochem.* (1988) 20(6):543-558 report that tin, cobalt, zinc

and manganese act as competitive inhibitors of the enzyme, while Neil et al., *J. of Ocular Pharmacology and Therapeutics* (1995) 11(3):455-468, and Maines, *Biochim. et Biophys. Acta* (1981) 673:339-350 concur that zinc and tin inhibit, but indicate that cobalt induces activity. Therefore, the role of the metalloporphyrins

5 in the prolongation of the survival of the graft will be associated with the modulation of heme oxygenase I activity.

The metalloprotoporphyrins of interest in this invention include iron, cobalt, tin, zinc, and manganese, particularly cobalt and zinc.

The subject compounds may be formulated in a variety of ways, depending

10 upon the nature of administration, the particular metalloprotoporphyrin, the number of administrations, other drugs, and the like. Therefore, the administration may vary with whether the donor, recipient or organ is being treated, the number of administrations, the manner of administration, the presence of other active components, and the like. The formulation will generally be in a physiologically

15 acceptable form, using various carriers, such as water, deionized water, phosphate buffered saline, aqueous ethanol, vegetable oils, etc. In some instances, the formulation may be formulated as a slow release formulation, where the subject compounds may be encapsulated in a wide variety of carriers, may be administered as capsules, or as a prodrug. The subject compounds may be taken parenterally or

20 orally, generally being administered intravascularly, subcutaneously, or intramuscularly. Depending upon the manner of administration, and the frequency of administration, the dosage will generally be in the range of about 0.5 to 50 mg/kg.

When bathing the organ in a composition comprising the subject compound,

25 conventional medium may be used, such as organ preservation solution. The temperature at which the organ may be maintained will be conventional, generally in the range of about 1° to 8°C. The residence time of the organ in the medium will generally be in the range of about 2 to 48 h, more usually 2 to 24 h.

When administered parenterally, generally the total amount of the subject

30 compound per day will generally be in the range of about 0.5 to 50, more usually in the range of about 1 to 25 mg/kg/day. This dose may be in a single bolus or be divided up to be administered in portions to provide the desired level of the subject compound in the host.

The subject compositions may be used with a wide variety of hosts, particularly primates, more particularly humans, or with domestic animals, and the like. The subject compositions may be used in conjunction with the transplantation of a wide variety of organs, such as kidney, heart, liver, spleen, bone marrow, pancreas, lung, islet of langerhans, etc.

The subject compositions may be used as adjunctive therapy iwth immunosuppressant compounds, such as cyclosporine, FK506, MHC Class I oligopeptides, or other immunosuppressants, where reduced amounts of the immunosuppressant may be used, generally reducing the amount employed by at least 25%, more usually at least 40% or more, from the therapeutic dosage for the indication.

Generally, the graft life will be extended for at least three days beyond what could normally be anticipated in the absence of the subject compound, more usually at least five days. This can be useful in areas where xenogeneic grafts have been used awaiting an allogenic graft, to allow for reduced amounts of immunosuppressants or avoid using immunosuppressants altogether.

The subject compounds may be used for allogenic, as well as xenogenic, grafts.

20

### EXPERIMENTAL

The following examples are offered by illustration and not by way of limitation.

#### **Materials and Methods**

*Animals:* Male, 7-8 week old CBA/J (H-2<sup>b</sup>) and C57BL/6/J (H-2<sup>b</sup>) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were maintained in our animal facility following Animal Welfare Guideline, Department of Health, CA.

*Synthetic Metalloporphyrins:* Various synthetic metalloporphyrins were purchased from Porphyrin Products, Inc. (Logan, UT). They were dissolved in 0.2 M NaOH, adjusted to pH 7.4. with 1 M HCl and subsequently diluted to 1 mg/ml in PBS.

*Cytotoxic T-cell Activity:* To assay the effect of metalloprotoporphyrins on cytotoxic T-cell activity, CBA to B6 effectors were generated following a five day

culture of  $3 \times 10^6$  CBA spleen cells with  $3 \times 10^6$  mitomycin-treated B6 spleen cells in wells of a 24-well plate (Nuncclone Delta, Nunc, Denmark) in R-10 medium. Effector cells were then harvested and washed. (H2b), a mouse lymphoma induced in C57BL/6N was used as target cells. EL4 cells were routinely subcultured once every three days. They were then collected, washed, and labeled with 0.1 mCi of sodium chromate-51 in 200  $\mu$ l for one hour at 37°C. Effector (E) and target (t) cells were added into V-shaped tissue culture plates (Nunc, Denmark) at E:T of 20:1. Metalloprotoporphyrins were diluted to the working concentrations with PBS and added at the beginning of the four hour incubation period. For the determination of maximal release, 1% triton X-100 was added to separate wells. Plates were centrifuged for three minutes to increase cellular contact before the four hour incubation period. After incubation 75  $\mu$ l supernatant from each well was collected and the amount of  $^{51}\text{Cr}$  released was counted using a TopCount scintillation counter. The degree of cell lysis was calculated using the formula below:

$$\% \text{ lysis} = \frac{CPM_{\text{experimental}} - CPM_{\text{spontaneous}}}{CPM_{\text{total}} - CPM_{\text{spontaneous}}} \times 100$$

*Heterotopic Heart Transplantation:* Abdominal heterotopic heart transplantation was performed as previously described by Ono and Lindsey (J. thorac. Cardiovasc. Surg. 1969 7:225-229) using C56B1/6 donors and CBA recipients. Metalloprophyrin was administered intraperitoneally using various protocols. Heart allograft survival was monitored daily by direct palpation, and rejection was defined as termination of palpable cardiac contractility. Results are expressed as percentage graft survival at a given postoperative period. Statistical analysis was performed with the Mann-Whitney test.

## Results

*Zinc- and cobalt-protoporphyrin inhibit cytotoxicity in vitro.* The effect of Zn- and Co-protoporphyrins on T- and NK-cell mediated cytotoxicity was evaluated in an *in vitro* four hour chromium release assay. Results of a representative experiment using cytotoxic T-cells are shown in Figure 1. Similar



results were observed in NK-cell assays. Addition, of protoporphyrin to the tissue culture inhibited target cell lysis in a dose dependent manner. At about 10  $\mu\text{g/ml}$  target cell lysis was inhibited completely (0% lysis). At even higher concentrations, chromium release from target cells in the presence of

- 5 protoporphyrins was lower than the spontaneous release observed in the absence of the compounds. These results demonstrate modulation of HO activity by metalloporphyrins results in inhibition of cytotoxicity *in vitro*.

- Zinc- and cobalt-protoporphyrin therapy of heart allograft recipients results in prolongation of graft survival.* The effect of metalloprotoporphyrins therapy on
- 10 heart allograft survival was evaluated in a mouse model. CBA recipients of C57B1/6 hearts were treated following transplantation with several doses of Zn- or co-protoporphyrin. Compared to control animals (mean survival time =  $7.8 \pm 1.1$ ) heart allograft survival was significantly prolonged to  $12.0 \pm 2.4$  ( $p=0.008$ ) and  $10.5 \pm 0.6$  ( $p=0.004$ ) days in Zn- or Co-protoporphyrin treated animals,
- 15 respectively. Pre-treatment of heart donors one day before transplantation resulted in a prolongation of graft survival to  $10.3 \pm 1.5$  days ( $p=0.03$ ).

It is evident from the above results, that by using metalloprotoporphyrins, one can greatly extend the survival of implants in a host. The compounds have few side effects and can be used safely with positive results.

- 20 All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

- The invention now being fully described, it will be apparent to one of
- 25 ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method for extending the survival of an organ transplant in a recipient, said method comprising:
  - 5 contacting said organ transplant with a metalloprotoporphyrin in an amount sufficient to extend the survival time of said transplant.
2. A method according to Claim 1, wherein said contacting is *ex vivo*.
- 10 3. A method according to Claim 1, wherein said contacting is in accordance with a prescribed regimen including day 1 subsequent to the transplantation of said organ in said recipient.
4. A method according to Claim 3, wherein said regimen comprises
  - 15 multiple dosages of said metalloprotoporphyrin within a period of two weeks.
5. A method according to Claim 3, wherein said regimen includes administering said metalloprotoporphyrin prior to transplant of said organ.
- 20 6. A method according to Claim 1, wherein said contacting includes administering said metalloprotoporphyrin to the donor of said organ prior to removal of said organ from said donor.
7. A method for extending the survival of an organ transplant in a
  - 25 recipient, said method comprising:  
administering parenterally to the recipient of said organ transplant at least one of a cobalt or zinc metalloprotoporphyrin in an amount sufficient to extend the survival time of said transplant, said administering including at least day one after the transplant.
- 30 8. A method according to Claim 7, wherein said administering includes repeated dosages during a period of two weeks after said transplant.

9. A method according to Claim 8, wherein said transplant is an allograft.

10. A method according to Claim 9, wherein said allograft is a heart.

5

11. A method according to Claim 8, wherein said metalloprotoporphyrin is zinc metalloprotoporphyrin.

12. A method according to Claim 8, wherein said metalloprotoporphyrin is cobalt metalloprotoporphyrin.

10

13. A method for extending the survival of an organ transplant in a recipient, said method comprising:

contacting said organ transplant with a compound capable of modulating heme oxygenase I activity in an amount sufficient to extend the survival time of said transplant.

15




FIGURE 1




FIGURE 2



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/40, 31/555</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/09618</b> <b>(43) International Publication Date:</b> 12 March 1998 (12.03.98)
<b>(21) International Application Number:</b> PCT/US97/15572 <b>(22) International Filing Date:</b> 3 September 1997 (03.09.97) <b>(30) Priority Data:</b> 08/709,650 9 September 1996 (09.09.96) US <b>(71) Applicant:</b> SANGSTAT MEDICAL CORPORATION [US/US]; 1505-B Adams Drive, Menlo Park, CA 94025 (US). <b>(72) Inventors:</b> BUELOW, Roland; 2747 Ross Road, Palo Alto, CA 94303 (US). WOO, Jacky; 620 Iris Avenue #422, Sunnyvale, CA 94086 (US). IYER, Suhasini; 1 Elmwood Drive, San Ramon, CA 94583 (US). <b>(74) Agents:</b> CHICKERING, Robert, B. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW. ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 7 May 1998 (07.05.98)	
<b>(54) Title:</b> GRAFT SURVIVAL PROLONGATION WITH PORPHYRINS  <b>(57) Abstract</b>  Metalloporphyrins are administered in conjunction with transplantation to enhance the survival of the organ.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 A61K31/40 A61K31/555		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 09038 A (WILLIAM HARVEY RESEARCH LIMITED) 28 March 1996 see claims 1,11-14 see page 11, line 17 - page 12, line 2 see page 13, line 14 - line 27	1-13
Y	C. J. SINAL ET AL: "Liver transplantation induces cytochrome P450 1A1 dependent monooxygenase activity in rat lung and kidney" CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 73, 1995, pages 146-152, XP002055471 see abstract  -/-	1-13
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search  12 February 1998		Date of mailing of the international search report  1 1. 03. 98
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Siatou, E

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15572

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	D. WILLIS ET AL: "Heme oxygenase: A novel target for the modulation of the inflammatory response" NATURE MEDICINE, vol. 2, no. 1, January 1996, pages 87-90, XP002055472 cited in the application see abstract see page 89, left-hand column, line 4 - line 45	1-13
A	--- P. MARTASEK ET AL: "Properties of human kidney heme oxygenase: Inhibition by synthetic heme analogues and metalloporphyrins" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 157, no. 2, 15 December 1988, pages 480-487, XP002055473 see page 485; table 4 see page 485	1-13
A	--- T. K. NEIL ET AL: "Modulation of Corneal Heme Oxygenase Expression by Oxidative Stress Agents" JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 11, no. 3, 1995, pages 455-468, XP002055474 cited in the application see abstract -----	1-13



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/15572

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/15572

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 1, 3-6, 13 partially and 7-12

because they relate to subject matter not required to be searched by this Authority, namely:

1. Claims 1, 3-6 and 13 insofar as they refer to an in vivo method of treatment are excluded from patentability (Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy)

refer to a method of treatment of the human body (Rule 39.1(iv) PCT)

Remark : Although claims 1, 3-6 and 13 insofar as they are directed to an in vivo method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Information on patent family members

Intern: at Application no

PCT/US 97/15572

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9609038 A	28-03-96	CA 2132690 A	23-03-96
		AU 3528195 A	09-04-96
		EP 0782441 A	09-07-97
-----			

**THIS PAGE BLANK (USPTO)**